|
|
THE PULSE OF GLOBAL PHARMA REGULATION
|
| |
|
EUROPE · EMA INTELLIGENCE
EU edition · 2026-02
|
|
| |
|
|
| |
|
|
REGULATORY · MHRA
Consultation on CE-Marked Devices in Great Britain
The MHRA launched a consultation on 16 February 2026 regarding the indefinite recognition of CE-marked devices compliant with EU MDR/IVDR in Great Britain, open until 10 April 2026.
|
|
| |
|
|
REGULATORY · EMA
Implementation of ICH E2D Guideline
EMA has released a strategy for implementing the ICH E2D guideline on post-approval safety data, effective from 18 March 2026.
|
|
| |
|
ARTICLE
EMA's New Guidance on Post-Authorisation Variations
The European Medicines Agency (EMA) has published updated guidance on the classification of variations post-authorisation. This includes a Q&A on manufacturing processes, stability testing, and the implementation of the PACMP and PLCM...
|
|
| |
|
NEWS
Overview of APAC Regulatory Changes
The APAC region continues to evolve its regulatory frameworks, focusing on harmonization and compliance with international standards, particularly in the medical device sector.
|
|
| |
|
|
NEWS
Increased Collaboration Among APAC Regulators
Regulatory bodies in the APAC region are enhancing collaboration to streamline approval processes and share best practices, aiming for greater efficiency in market access.
|
|
| |
|
Official sources
- https://www.ema.europa.eu/en/documents/report/final-programming-document-2026-28_en.pdf
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://www.ema.europa.eu/en
|
|
www.novapharmanews.com
Trusted by manufacturing, regulatory affairs, and quality teams across Europe.
EU
· Edition 2026-02
· B2B pharma intelligence, generated and reviewed by editors.
© NovaPharmaNews. Trusted pharmaceutical intelligence covering FDA, EMA, NMPA, and PMDA regulatory developments across global markets.
|